Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

- Several Potential Catalysts Expected in Next Six Months -

BRISBANE, Calif., July 31 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the second quarter and six months ended June 30, 2008. InterMune reported a net loss for the second quarter of 2008 of $26.5 million, or $0.68 per share, compared with a net loss of $19.8 million, or $0.58 per share, in the second quarter of 2007.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "The second quarter of 2008 was an exciting period for InterMune. We reported substantial progress on our collaboration with Roche with ITMN-191 (R7227) by reporting top-line results from our 14-day monotherapy study, reporting the successful completion of 13-week preclinical toxicology studies in two species that enable our Phase 2 studies and announcing the initiation of our 14-day study of ITMN-191 plus standard of care therapy."

Mr. Welch continued, "The next six months will be a very rich period in terms of data and milestones for InterMune. At the AASLD meeting in late October, we expect to present the results of our two completed clinical studies of ITMN-191 as well as the results of non-clinical studies of ITMN-191 in combination with direct antiviral compounds in the Roche portfolio. During the fourth quarter, we expect to announce top-line results from our on-going 14-day study of ITMN-191 plus standard of care therapy and in January of 2009, we expect to report top-line results from our Phase 3 CAPACITY program for pirfenidone in idiopathic pulmonary fibrosis, a fatal disease for which no treatments are approved."

Results for Second Quarter 2008

InterMune reported total revenue in the s
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma ... a recommended approach for protecting personal data in ... researchers, patients and others. The document describes an ... information from CSRs and other related clinical trial ... The goal of the TransCelerate CSR Redaction ...
(Date:9/2/2014)... September 02, 2014 Myriant Corporation, ... signage of a distribution agreement with Azelis Group, ... distributing Myriant’s bio-succinic acid in the Nordics, Benelux, ... targeting customers in the industrial and base chemicals ... Azelis offers a far-reaching chemical portfolio with extensive ...
(Date:9/2/2014)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... (PTO) has issued a patent related to NB32, the ... is a fixed-dose combination of naltrexone sustained release (SR) ... claims methods for treating insulin resistance using a composition ... If NB32 is approved for use in ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
Breaking Biology Technology:TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... presented today show that RAPAFLO(R) (silodosin) significantly reduced ... pain syndrome (CP/CPPS).  In the study presented at ... RAPAFLO(R) also significantly improved urinary symptoms as well ... pelvic pain syndrome (CP/CPPS) is a common condition ...
... 2011 Brian Olson didn,t exactly fit the image of an ... first to admit it. "I had just a GED and was ... math." With a vague notion that he wanted to ... enrolled in basic chemistry and biology courses as a freshman. ...
... May 17, 2011 P f enex ... has submitted a Biologics Master File (BMF) to the United ... carrier protein to support the development of conjugate vaccine products ... supplying cGMP grade CRM197 carrier protein to multiple partners in ...
Cached Biology Technology:Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 2Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 3Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 4Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 5Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 6From GED to PhD: Borough of Manhattan Community College's Brian Olson Faces Academic Deficits Only to Be Rewarded with Acceptance to CUNY's PhD Program in Biochemistry 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3
(Date:9/2/2014)... lithographic limestone is well known as a result ... area (for example, Archaeopteryx). Now, for the first ... French equivalent of these outcrops - discoveries which ... water treader. , Despite the abundance of fossils ... been obtained from the Late Kimmeridgian equivalents of ...
(Date:9/2/2014)... stride; others are done in by it. New research ... this so-called stress gap in mice with very similar ... to better understand the development of psychiatric disorders such ... has unique experiences as it goes through its life. ... the expression of genes, and as a result, affect ...
(Date:9/1/2014)... U.S. has improved steadily in recent yearsspurred in large ... remains poor and disparities continue to widen among socioeconomic ... Harvard School of Public Health (HSPH). , "The study ... extensive efforts by many groups and individuals to improve ... also indicates that these efforts need to be expanded," ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... has identified a lung protein that appears to play ... an antibody to block its activity, Indiana University scientists ... the protein, a cytokine named EMAPII, could provide a ... M.D., associate professor of medicine at the Indiana University ...
... take to regenerate a limb? Biologists have long thought that ... cells that can generate any tissue in the body. But ... regrow the complete organ, at least in zebrafish. Researchers ... shown that cells capable of regenerating a zebrafish fin do ...
... has worked with wireless sensor network developers Senceive, ... across critical structures in the UK that will ... Senceive,s main application area is long-term infrastructure monitoring. ... used to assess the condition of railway structures, ...
Cached Biology News:Protein could offer target to reduce lung damage from smoking-caused emphysema 2Zebrafish regrow fins using multiple cell types, not identical stem cells 2NPL helps Senceive to offer improved monitoring of structural assets across the UK 2
... Monoclonal Mouse Antibody to Cytokeratin 5 / ... a high molecular weight, basic type of ... the superficial cell layers of stratified epithelia ... and in mesothelial cells and mesothelioma. Cytokeratin ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Biology Products: